Marcus Maurer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4369166/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature, 2000, 408, 57-63.	27.8	1,099
2	The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1393-1414.	5.7	1,008
3	The <scp>EAACI</scp> / <scp>GA</scp> ² <scp>LEN</scp> / <scp>EDF</scp> / <scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 868-887.	5.7	912
4	Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. New England Journal of Medicine, 2013, 368, 924-935.	27.0	838
5	Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 317-330.	5.7	597
6	EAACI/GA ² LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1417-1426.	5.7	582
7	Macrophage inflammatory protein-1. International Journal of Biochemistry and Cell Biology, 2004, 36, 1882-1886.	2.8	576
8	EAACI/GA²LEN/EDF/WAO guideline: management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1427-1443.	5.7	502
9	A Comprehensive Guide for the Recognition and Classification of Distinct Stages of Hair Follicle Morphogenesis. Journal of Investigative Dermatology, 1999, 113, 523-532.	0.7	501
10	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. Journal of Allergy and Clinical Immunology, 2012, 130, 1049-1062.	2.9	486
11	Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema. New England Journal of Medicine, 2010, 363, 532-541.	27.0	477
12	Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. Journal of Allergy and Clinical Immunology, 2013, 132, 101-109.	2.9	461
13	Rupatadine in allergic rhinitis and chronic urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 5-28.	5.7	458
14	The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 734-766.	5.7	392
15	Risk of firstâ€generation H ₁ â€antihistamines: a GA ² LEN position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 459-466.	5.7	371
16	The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1575-1596.	5.7	365
17	Mast cells as sentinels of innate immunity. Current Opinion in Immunology, 1999, 11, 53-59.	5.5	359
18	A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria. Journal of Allergy and Clinical Immunology, 2011, 128, 567-573.e1.	2.9	332

#	Article	IF	CITATIONS
19	How to assess disease activity in patients with chronic urticaria?. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 777-780.	5.7	327
20	Mast Cells Can Secrete Vascular Permeability Factor/ Vascular Endothelial Cell Growth Factor and Exhibit Enhanced Release after Immunoglobulin E–dependent Upregulation of Fcε Receptor I Expression. Journal of Experimental Medicine, 1998, 188, 1135-1145.	8.5	320
21	Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H 1 Antihistamines: A Randomized, Placebo-Controlled Study. Journal of Investigative Dermatology, 2015, 135, 67-75.	0.7	307
22	Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. Journal of Allergy and Clinical Immunology, 2011, 128, 202-209.e5.	2.9	303
23	Control of murine hair follicle regression (catagen) by TGFâ€Î²1 <i>in vivo</i> . FASEB Journal, 2000, 14, 752-760.	0.5	301
24	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. Journal of Allergy and Clinical Immunology, 2016, 137, 35-45.	2.9	289
25	EAACI/GA ² LEN/EDF guideline: management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 321-331.	5.7	278
26	Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature, 2004, 432, 512-516.	27.8	275
27	EAACI/GA ² LEN task force consensus report: the autologous serum skin test in urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1256-1268.	5.7	272
28	Development and validation of the Urticaria Control Test: AÂpatient-reported outcome instrument for assessing urticaria control. Journal of Allergy and Clinical Immunology, 2014, 133, 1365-1372.e6.	2.9	268
29	The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA ² LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 780-802.	5.7	268
30	Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature, 1997, 390, 172-175.	27.8	266
31	Mast cells – key effector cells in immune responses. Trends in Immunology, 2007, 28, 234-241.	6.8	264
32	Epidemiology of urticaria: a representative cross-sectional population survey. Clinical and Experimental Dermatology, 2010, 35, 869-873.	1.3	264
33	WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organization Journal, 2012, 5, 182-199.	3.5	264
34	Mast cells are required for normal healing of skin wounds in mice. FASEB Journal, 2006, 20, 2366-2368.	0.5	263
35	Autoimmune chronic spontaneous urticaria: What we know and what we do not know. Journal of Allergy and Clinical Immunology, 2017, 139, 1772-1781.e1.	2.9	240
36	Neurophysiological, Neuroimmunological, and Neuroendocrine Basis of Pruritus. Journal of Investigative Dermatology, 2006, 126, 1705-1718.	0.7	231

#	Article	IF	CITATIONS
37	Schnitzler's syndrome: diagnosis, treatment, and followâ€up. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 562-568.	5.7	224
38	Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. Journal of Dermatological Science, 2014, 73, 57-62.	1.9	222
39	EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 316-320.	5.7	221
40	Omalizumab for the treatment of chronic spontaneous urticaria: AÂmeta-analysis of randomized clinical trials. Journal of Allergy and Clinical Immunology, 2016, 137, 1742-1750.e4.	2.9	220
41	IgE Mediated Autoallergy against Thyroid Peroxidase – A Novel Pathomechanism of Chronic Spontaneous Urticaria?. PLoS ONE, 2011, 6, e14794.	2.5	216
42	Prevalence of chronic urticaria in children and adults across the globe: Systematic review with metaâ€analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 423-432.	5.7	213
43	Characterization of Functional Vanilloid Receptors Expressed by Mast Cells. Blood, 1998, 91, 1332-1340.	1.4	208
44	The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2015, 135, 337-342.e2.	2.9	208
45	The burden of chronic spontaneous urticaria is substantial: Realâ€world evidence from <scp>ASSURE</scp> â€ <scp>CSU</scp> . Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 2005-2016.	5.7	197
46	Melanogenesis During the Anagen-Catagen-Telogen Transformation of the Murine Hair Cycle. Journal of Investigative Dermatology, 1994, 102, 862-869.	0.7	190
47	Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. British Journal of Dermatology, 2006, 154, 294-298.	1.5	189
48	What is the physiological function of mast cells?. Experimental Dermatology, 2003, 12, 886-886.	2.9	187
49	High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study. Journal of Allergy and Clinical Immunology, 2009, 123, 672-679.	2.9	187
50	Omalizumab treatment in patients with chronic inducible urticaria: AÂsystematic review of published evidence. Journal of Allergy and Clinical Immunology, 2018, 141, 638-649.	2.9	187
51	Ligelizumab for Chronic Spontaneous Urticaria. New England Journal of Medicine, 2019, 381, 1321-1332.	27.0	187
52	Development and construct validation of the angioedema quality of life questionnaire. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1289-1298.	5.7	182
53	Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks. JAMA - Journal of the American Medical Association, 2018, 320, 2108.	7.4	174
54	Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2017, 139, 1059-1061.e1.	2.9	167

#	Article	IF	CITATIONS
55	IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2018, 142, 876-882.	2.9	167
56	The role and relevance of mast cells in urticaria. Immunological Reviews, 2018, 282, 232-247.	6.0	165
57	IL-9 Production by Regulatory T Cells Recruits Mast Cells That Are Essential for Regulatory T Cell-Induced Immune Suppression. Journal of Immunology, 2011, 186, 83-91.	0.8	160
58	MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1372-1392.	5.7	160
59	Mast cells as initiators of immunity and host defense. Experimental Dermatology, 2001, 10, 1-10.	2.9	159
60	Mast Cell Involvement in Murine Hair Growth. Developmental Biology, 1994, 163, 230-240.	2.0	158
61	<scp>EAACI</scp> taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 27-36.	5.7	158
62	TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment. Blood, 2005, 106, 978-987.	1.4	157
63	The c-kit Ligand, Stem Cell Factor, Can Enhance Innate Immunity Through Effects on Mast Cells. Journal of Experimental Medicine, 1998, 188, 2343-2348.	8.5	156
64	The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1961-1990.	5.7	153
65	The role of ILâ€33 and mast cells in allergy and inflammation. Clinical and Translational Allergy, 2015, 5, 33.	3.2	152
66	Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide Perspective. World Allergy Organization Journal, 2012, 5, 125-147.	3.5	150
67	The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 705-712.	5.7	150
68	The global burden of chronic urticaria for the patient and society*. British Journal of Dermatology, 2021, 184, 226-236.	1.5	150
69	Successful treatment of solar urticaria with antiâ€immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1563-1565.	5.7	149
70	Development, validation, and initial results of the Angioedema Activity Score. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1185-1192.	5.7	147
71	New topics in bradykinin research. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1397-1406.	5.7	146
72	Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature, 2021, 600, 295-301.	27.8	146

#	Article	IF	CITATIONS
73	The German version of the chronic urticaria qualityâ€ofâ€life questionnaire: factor analysis, validation, and initial clinical findings. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 927-936.	5.7	145
74	Mast cells orchestrate type 2 immunity to helminths through regulation of tissue-derived cytokines. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6644-6649.	7.1	145
75	SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself. Nature Communications, 2021, 12, 1961.	12.8	145
76	The definition and diagnostic testing of physical and cholinergic urticarias – EAACI/GA ² LEN/EDF/UNEV consensus panel recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1715-1721.	5.7	143
77	Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1267-1274.	5.7	139
78	Pattern analysis of human cutaneous mast cell populations by total body surface mapping. British Journal of Dermatology, 2003, 148, 224-228.	1.5	137
79	Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2427-2436.	5.7	136
80	Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria. International Archives of Allergy and Immunology, 2011, 154, 177-180.	2.1	133
81	Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1α/β released from neutrophils recruited by mast cell–derived TNFα. Blood, 2003, 101, 210-215.	1.4	130
82	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	2.9	128
83	Autoimmune comorbidity in chronic spontaneous urticaria: A systematic review. Autoimmunity Reviews, 2017, 16, 1196-1208.	5.8	125
84	Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1440-1460.	5.7	124
85	Skin mast cells control T cellâ€dependent host defense in Leishmania major infections. FASEB Journal, 2006, 20, 2460-2467.	0.5	123
86	Retreatment With Omalizumab Results in Rapid Remission in Chronic Spontaneous and Inducible Urticaria. JAMA Dermatology, 2014, 150, 288.	4.1	123
87	Molecular targets on mast cells and basophils for novel therapies. Journal of Allergy and Clinical Immunology, 2014, 134, 530-544.	2.9	123
88	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47.	3.2	121
89	Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial. Dermatology, 2006, 212, 150-159.	2.1	120
90	Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA ² LEN project. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 671-680.	5.7	119

#	Article	IF	CITATIONS
91	Undertreatment of rhinitis symptoms in Europe: findings from a crossâ€sectional questionnaire survey. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1057-1063.	5.7	119
92	International consensus on hereditary and acquired angioedema. Annals of Allergy, Asthma and Immunology, 2012, 109, 395-402.	1.0	118
93	p53 is essential for chemotherapy-induced hair loss. Cancer Research, 2000, 60, 5002-6.	0.9	118
94	Immunoglobulin E-Mediated Autoimmunity. Frontiers in Immunology, 2018, 9, 689.	4.8	116
95	Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. European Journal of Immunology, 2011, 41, 1883-1893.	2.9	115
96	A simple immunofluorescence technique for simultaneous visualization of mast cells and nerve fibers reveals selectivity and hair cycle - dependent changes in mast cell - nerve fiber contacts in murine skin. Archives of Dermatological Research, 1997, 289, 292-302.	1.9	114
97	Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet Journal of Rare Diseases, 2018, 13, 73.	2.7	114
98	Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment. PLoS ONE, 2013, 8, e53773.	2.5	113
99	Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal) Tj ETQq1 1 0.7843 Dermatology, 2015, 172, 1294-1302.	14 rgBT / 1.5	Overlock 10 113
100	Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Theranostics, 2017, 7, 1266-1276.	10.0	113
101	Successful treatment of cholinergic urticaria with antiâ€immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 247-249.	5.7	112
102	High Prevalence of Mental Disorders and Emotional Distress in Patients with Chronic Spontaneous Urticaria. Acta Dermato-Venereologica, 2011, 91, 557-561.	1.3	110
103	Efficacy and safety of the interleukinâ€1 antagonist rilonacept in <scp>S</scp> chnitzler syndrome: an openâ€label study. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 943-950.	5.7	110
104	Definition, aims, and implementation of <scp>GA</scp> ² <scp>LEN</scp> Urticaria Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1210-1218.	5.7	110
105	Upâ€dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 921-928.	5.7	109
106	Urticaria: Current Opinions about Etiology, Diagnosis and Therapy. Acta Dermato-Venereologica, 2007, 87, 196-205.	1.3	109
107	Interleukinâ€31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 113-117.	5.7	108
108	Effect of omalizumab on angioedema in H ₁ â€antihistamineâ€resistant chronic spontaneous urticaria patients: results from Xâ€ <scp>ACT</scp> , a randomized controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1135-1144.	5.7	108

#	Article	IF	CITATIONS
109	Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. International Archives of Allergy and Immunology, 2020, 181, 321-333.	2.1	108
110	Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy, Asthma and Clinical Immunology, 2013, 9, 29.	2.0	107
111	Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clinical and Experimental Dermatology, 2007, 32, 241-245.	1.3	105
112	Mast cell functions in the innate skin immune system. Immunobiology, 2008, 213, 251-260.	1.9	104
113	The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders. Molecular Immunology, 2015, 63, 80-85.	2.2	103
114	Mast Cells as Drivers of Disease and Therapeutic Targets. Trends in Immunology, 2018, 39, 151-162.	6.8	103
115	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. Journal of Allergy and Clinical Immunology, 2019, 143, 864-879.	2.9	103
116	IL-15 constrains mast cell–dependent antibacterial defenses by suppressing chymase activities. Nature Medicine, 2007, 13, 927-934.	30.7	102
117	Substance P as an Immunomodulatory Neuropeptide in a Mouse Model for Autoimmune Hair Loss (Alopecia Areata). Journal of Investigative Dermatology, 2007, 127, 1489-1497.	0.7	102
118	Effects of a pseudoallergenâ€free diet on chronic spontaneous urticaria: a prospective trial. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 78-83.	5.7	102
119	Migration of Melanoblasts into the Developing Murine Hair Follicle Is Accompanied by Transient c-Kit Expression. Journal of Histochemistry and Cytochemistry, 2002, 50, 751-766.	2.5	99
120	Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. British Journal of Dermatology, 2009, 160, 633-641.	1.5	98
121	A Role for CD21/CD35 and CD19 in Responses to Acute Septic Peritonitis: A Potential Mechanism for Mast Cell Activation. Journal of Immunology, 2000, 165, 6915-6921.	0.8	97
122	Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Annals of Allergy, Asthma and Immunology, 2012, 108, 20-24.	1.0	97
123	From seafood waste to active seafood packaging: An emerging opportunity of the circular economy. Journal of Cleaner Production, 2019, 208, 86-98.	9.3	97
124	H1â€antihistamineâ€refractory chronic spontaneous urticaria: it's worse than we thought – first results of the multicenter realâ€life <scp>AWARE</scp> study. Clinical and Experimental Allergy, 2017, 47, 684-692.	2.9	96
125	Physical Urticarias and Cholinergic Urticaria. Immunology and Allergy Clinics of North America, 2014, 34, 73-88.	1.9	95
126	Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with Iowâ€level persistence in uninvolved skin. British Journal of Dermatology, 2014, 171, 505-511.	1.5	93

#	Article	IF	CITATIONS
127	Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 318-325.e5.	3.8	93
128	Recommendations for assessing Patientâ€Reported Outcomes and Healthâ€Related quality of life in clinical trials on allergy: a GA ² LEN taskforce position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 290-295.	5.7	92
129	The Angioedema Quality of Life Questionnaire (<scp>AE</scp> â€QoL) – assessment of sensitivity to change and minimal clinically important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1203-1209.	5.7	92
130	Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2017, 140, 864-867.e5.	2.9	92
131	Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRIâ€mediated signaling. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1966-1978.	5.7	92
132	Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Experimental Dermatology, 2009, 18, 437-444.	2.9	91
133	Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 586-599.	3.8	91
134	Hair Cycle-Dependent Changes in Adrenergic Skin Innervation, and Hair Growth Modulation by Adrenergic Drugs. Journal of Investigative Dermatology, 1999, 113, 878-887.	0.7	90
135	Efficacy and safety of canakinumab in Schnitzler syndrome: AÂmulticenter randomized placebo-controlled study. Journal of Allergy and Clinical Immunology, 2017, 139, 1311-1320.	2.9	89
136	Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema. New England Journal of Medicine, 2018, 379, 352-362.	27.0	89
137	Immediate contact skin reactions, an update of Contact Urticaria, Contact Urticaria Syndrome and Protein Contact Dermatitis "A Never Ending Story". European Journal of Dermatology, 2010, 20, 552-62.	0.6	89
138	The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20Âmg. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1088-1091.	2.4	87
139	Chronic spontaneous urticaria in children: Itching for insight. Pediatric Allergy and Immunology, 2011, 22, 1-8.	2.6	87
140	Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Archives of Dermatological Research, 1995, 287, 500-502.	1.9	86
141	Chronic spontaneous urticaria and internal parasites – a systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 308-322.	5.7	85
142	Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. Journal of Immunology, 1998, 161, 6463-7.	0.8	85
143	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA ² LEN – ARIA Position Paper. International Archives of Allergy and Immunology, 2012, 158, 216-231.	2.1	83
144	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 735-750.	5.7	83

#	Article	IF	CITATIONS
145	Chronic urticaria: a patient survey on qualityâ€ofâ€life, treatment usage and doctor–patient relation. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 581-588.	5.7	82
146	Successful treatment of delayed pressure urticaria with anti–TNF-α. Journal of Allergy and Clinical Immunology, 2007, 119, 752-754.	2.9	81
147	New treatments for chronic urticaria. Annals of Allergy, Asthma and Immunology, 2020, 124, 2-12.	1.0	81
148	Control of Pseudomonas aeruginosa Skin Infections in Mice Is Mast Cell-Dependent. American Journal of Pathology, 2007, 170, 1910-1916.	3.8	80
149	Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. American Journal of Pathology, 1997, 150, 1433-41.	3.8	80
150	Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Annals of Allergy, Asthma and Immunology, 2016, 117, 394-398.	1.0	78
151	The Urticaria Activity Score—Validity, Reliability, and Responsiveness. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1185-1190.e1.	3.8	78
152	The role of mast cells in neuroinflammation. Acta Neuropathologica, 2013, 125, 637-650.	7.7	76
153	Potential blood biomarkers in chronic spontaneous urticaria. Clinical and Experimental Allergy, 2017, 47, 19-36.	2.9	76
154	Mast cell–driven skin inflammation is impaired in the absence of sensory nerves. Journal of Allergy and Clinical Immunology, 2008, 121, 955-961.	2.9	75
155	Methods report on the development of the 2013 revision and update of the <scp>EAACI</scp> / <scp>GA²LEN</scp> EDF/ <scp>WAO</scp> guideline for the definition, classification, diagnosis, and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, e1-29	5.7	75
156	Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: AÂrandomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology, 2021, 148, 164-172.e9.	2.9	75
157	How not to miss autoinflammatory diseases masquerading as urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1465-1474.	5.7	74
158	Mast cells rescue implantation defects caused by c-kit deficiency. Cell Death and Disease, 2013, 4, e462-e462.	6.3	74
159	Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from <scp>ASSURE</scp> â€ <scp>CSU</scp> . Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1724-1734.	5.7	74
160	Executive summary of the methods report for â€~The EAACI/GA ² LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update'. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1145-1146.	5.7	74
161	Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2406-2408.	5.7	74
162	p53 Involvement in the Control of Murine Hair Follicle Regression. American Journal of Pathology, 2001, 158, 1913-1919.	3.8	73

#	Article	IF	CITATIONS
163	The role of interleukin-1 in allergy-related disorders. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 477-484.	2.3	73
164	Omalizumab is effective in symptomatic dermographism—results of a randomized placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2017, 140, 870-873.e5.	2.9	73
165	Autoimmune chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2022, 149, 1819-1831.	2.9	73
166	Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 596-604.	5.7	72
167	Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 840-844.	5.7	72
168	Microbiotaâ€dependent and â€independent effects of dietary fibre on human health. British Journal of Pharmacology, 2020, 177, 1363-1381.	5.4	72
169	Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nature Reviews Immunology, 2022, 22, 294-308.	22.7	72
170	Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2012, 129, 848-850.	2.9	70
171	Mas-related G protein–coupled receptor X2 and its activators in dermatologic allergies. Journal of Allergy and Clinical Immunology, 2021, 147, 456-469.	2.9	70
172	The ingenious mast cell: Contemporary insights into mast cell behavior and function. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 83-99.	5.7	69
173	Responsiveness and minimal important difference of the urticaria control test. Journal of Allergy and Clinical Immunology, 2017, 140, 1710-1713.e11.	2.9	68
174	Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. Journal of Allergy and Clinical Immunology, 2009, 123, 705-706.	2.9	67
175	Chronic inducible urticaria: AÂsystematic review of treatment options. Journal of Allergy and Clinical Immunology, 2018, 141, 1726-1734.	2.9	66
176	Predictors of treatment response in chronic spontaneous urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2965-2981.	5.7	66
177	Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis. European Journal of Immunology, 2005, 35, 3074-3082.	2.9	64
178	The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria. Journal of Allergy and Clinical Immunology, 2018, 141, 1138-1139.e7.	2.9	64
179	Câ€reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 940-948.	5.7	64
180	Treatment of urticarial vasculitis: AÂsystematic review. Journal of Allergy and Clinical Immunology, 2019, 143, 458-466.	2.9	64

#	Article	IF	CITATIONS
181	Peltier effect–based temperature challenge: An improved method for diagnosing cold urticaria. Journal of Allergy and Clinical Immunology, 2004, 114, 1224-1225.	2.9	63
182	Hereditary angioedema: Molecular and clinical differences among European populations. Journal of Allergy and Clinical Immunology, 2015, 135, 570-573.e10.	2.9	63
183	How to Approach Chronic Inducible Urticaria. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1119-1130.	3.8	63
184	Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA ² LEN taskforce position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 959-968.	5.7	62
185	Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Annals of Allergy, Asthma and Immunology, 2010, 104, 86-92.	1.0	62
186	Physical Urticaria. Current Allergy and Asthma Reports, 2012, 12, 281-287.	5.3	62
187	Murine skin as a target for melatonin bioregulation. Experimental Dermatology, 1994, 3, 45-50.	2.9	61
188	Mast cells as modulators of hair follicle cycling. Experimental Dermatology, 1995, 4, 266-271.	2.9	61
189	The mast cell products histamine and serotonin stimulate and TNF-α inhibits the proliferation of murine epidermal keratinocytes in situ. Journal of Dermatological Science, 1997, 16, 79-84.	1.9	61
190	Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 303-305.	5.7	61
191	Substance P Is Upregulated in the Serum of Patients with Chronic Spontaneous Urticaria. Journal of Investigative Dermatology, 2014, 134, 2833-2836.	0.7	61
192	Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 743-750.e1.	3.8	61
193	ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice. British Journal of Dermatology, 2016, 174, 892-894.	1.5	61
194	A Review of International Recommendations for the Diagnosis and Management of Chronic Urticaria. Acta Dermato-Venereologica, 2017, 97, 149-158.	1.3	61
195	Biologics for the Use in Chronic Spontaneous Urticaria: When and Which. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1067-1078.	3.8	61
196	Management and treatment of chronic urticaria (<scp>CU</scp>). Journal of the European Academy of Dermatology and Venereology, 2015, 29, 16-32.	2.4	60
197	A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2016, 138, 1730-1732.	2.9	60
198	Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. British Journal of Dermatology, 2010, 162, 674-676.	1.5	59

#	Article	IF	CITATIONS
199	Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. Journal of Allergy and Clinical Immunology, 2010, 126, 665-666.	2.9	59
200	Management of chronic spontaneous urticaria in real life – in accordance with the guidelines? A crossâ€sectional physicianâ€based survey study. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 43-50.	2.4	59
201	Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. Journal of the American Academy of Dermatology, 2017, 76, 648-654.e2.	1.2	59
202	The role of eosinophils in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2020, 145, 1510-1516.	2.9	59
203	Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 59-70.	5.7	58
204	The global impact of the COVIDâ€19 pandemic on the management and course of chronic urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 816-830.	5.7	58
205	Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. Journal of Allergy and Clinical Immunology, 2007, 120, 213-215.	2.9	57
206	Innate immunity and allergy in the skin. Current Opinion in Immunology, 2009, 21, 687-693.	5.5	57
207	Looking forward to new targeted treatments for chronic spontaneous urticaria. Clinical and Translational Allergy, 2017, 7, 1.	3.2	57
208	Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. Pediatric Allergy and Immunology, 2018, 29, 630-636.	2.6	57
209	Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema. Journal of Investigational Allergology and Clinical Immunology, 2016, 26, 383-386.	1.3	57
210	Comorbidity and pathogenic links of chronic spontaneous urticaria and systemic lupus erythematosus – a systematic review. Clinical and Experimental Allergy, 2016, 46, 275-287.	2.9	56
211	How best to fight that nasty itch - from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Experimental Dermatology, 2005, 14, 225-225.	2.9	55
212	Mast cells are critical for controlling the bacterial burden and the healing of infected wounds. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20500-20504.	7.1	55
213	Total IgE as a Marker for Chronic Spontaneous Urticaria. Allergy, Asthma and Immunology Research, 2021, 13, 206.	2.9	55
214	Pharmacological Disruption of Hair Follicle Pigmentation by Cyclophosphamide as a Model for Studying the Melanocyte Response to and Recovery from Cytotoxic Drug Damage In Situ. Journal of Investigative Dermatology, 1996, 106, 1203-1211.	0.7	54
215	Who is really in control of skin immunity underphysiologicalcircumstances - lymphocytes, dendritic cells or keratinocytes?. Experimental Dermatology, 2006, 15, 913-916.	2.9	54
216	Role and Relevance of Mast Cells in Fungal Infections. Frontiers in Immunology, 2012, 3, 146.	4.8	54

#	Article	IF	CITATIONS
217	Transfer of regulatory T cells into abortion-prone mice promotes the expansion of uterine mast cells and normalizes early pregnancy angiogenesis. Scientific Reports, 2015, 5, 13938.	3.3	54
218	Cold urticaria – What we know and what we do not know. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1077-1094.	5.7	54
219	Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H ₁ â€antihistamine dose escalation. British Journal of Dermatology, 2012, 166, 1095-1099.	1.5	53
220	Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 816-819.	5.7	53
221	German Version of ItchyQoL: Validation and Initial Clinical Findings. Acta Dermato-Venereologica, 2013, 93, 562-568.	1.3	53
222	Treatment Strategies in Mastocytosis. Immunology and Allergy Clinics of North America, 2014, 34, 433-447.	1.9	53
223	Mast Cell Promotion of T Cell–Driven Antigenâ€Induced Arthritis Despite Being Dispensable for Antibodyâ€Induced Arthritis in Which T Cells Are Bypassed. Arthritis and Rheumatology, 2015, 67, 903-913.	5.6	53
224	Update on rupatadine in the management of allergic disorders. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1-24.	5.7	53
225	Mast cells: makers and breakers of allergic inflammation. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 427-430.	2.3	52
226	Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study. Journal of Allergy and Clinical Immunology, 2013, 132, 751-754.e5.	2.9	52
227	Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 964-971.	2.4	52
228	Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e112-e113.	2.4	52
229	Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nature Medicine, 2021, 27, 1961-1969.	30.7	52
230	The <i>status quo</i> and <i>quo vadis</i> of mast cells. Experimental Dermatology, 2005, 14, 923-929.	2.9	51
231	Inflammatory Murine Skin Responses to UV-B Light Are Partially Dependent on Endothelin-1 and Mast Cells. American Journal of Pathology, 2006, 169, 815-822.	3.8	51
232	Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. JDDG - Journal of the German Society of Dermatology, 2018, 16, 477-478.	0.8	51
233	Omalizumab rapidly improves angioedemaâ€related quality of life in adult patients with chronic spontaneous urticaria: Xâ€ <scp>ACT</scp> study data. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 576-584.	5.7	51
234	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. Frontiers in Medicine, 0, 9, .	2.6	51

#	Article	IF	CITATIONS
235	Kit Is Expressed by Epithelial Cells In Vivo. Journal of Investigative Dermatology, 2003, 121, 976-984.	0.7	50
236	The role of innate immunity in asthma: leads and lessons from mouse models. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 579-590.	5.7	50
237	Mast cells protect from post-traumatic spinal cord damage in mice by degrading inflammation-associated cytokines via mouse mast cell protease 4. Neurobiology of Disease, 2014, 62, 260-272.	4.4	50
238	Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 963-971.	3.8	50
239	Mast Cells Limit the Exacerbation of Chronic Allergic Contact Dermatitis in Response to Repeated Allergen Exposure. Journal of Immunology, 2016, 197, 4240-4246.	0.8	50
240	Comparison and interpretability of the available urticaria activity scores. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 251-255.	5.7	50
241	Validation of the Angioedema Control Test (AECT)—A Patient-Reported Outcome Instrument for Assessing Angioedema Control. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2050-2057.e4.	3.8	50
242	IgM and IgA in addition to IgG autoantibodies against FcɛRlα are frequent and associated with disease markers of chronic spontaneous urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3208-3215.	5.7	50
243	Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. British Journal of Dermatology, 2010, 162, 198-200.	1.5	49
244	<i>Fasciola hepatica</i> Tegumental Coat Impairs Mast Cells' Ability To Drive Th1 Immune Responses. Journal of Immunology, 2013, 190, 2873-2879.	0.8	49
245	Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria. Journal of Dermatological Science, 2014, 75, 88-93.	1.9	49
246	Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 25-32.	2.4	49
247	Omalizumab in chronic urticaria. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 406-411.	2.3	48
248	Regulation of type 2 immunity to helminths by mast cells. Gut Microbes, 2012, 3, 476-481.	9.8	48
249	Mast cells protect from postâ€traumatic brain inflammation by the mast cellâ€specific chymase <i>mouse mast cell proteaseâ€4</i> . FASEB Journal, 2013, 27, 920-929.	0.5	48
250	Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series. Pediatric Allergy and Immunology, 2015, 26, 585-588.	2.6	48
251	Symptomatic dermographism: an inadequately described disease. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 708-712.	2.4	48
252	Nonâ€pathogenic commensal <i>Escherichia coli</i> bacteria can inhibit degranulation of mast cells. Experimental Dermatology, 2008, 17, 427-435.	2.9	47

#	Article	IF	CITATIONS
253	H1-Antihistamine Up-Dosing in Chronic Spontaneous Urticaria: Patients' Perspective of Effectiveness and Side Effects – A Retrospective Survey Study. PLoS ONE, 2011, 6, e23931.	2.5	47
254	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016, 6, 29.	3.2	47
255	Development of the Angioedema Control Test—A patientâ€reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1165-1177.	5.7	47
256	An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. Journal of Allergy and Clinical Immunology, 2022, 149, 1683-1690.e7.	2.9	47
257	Antihistamineâ€resistant urticaria factitia successfully treated with antiâ€immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1494-1495.	5.7	46
258	Rupatadine improves quality of life in mastocytosis: a randomized, doubleâ€blind, placeboâ€controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 949-952.	5.7	46
259	Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 305-314.	5.7	46
260	Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. British Journal of Dermatology, 2017, 177, 1093-1101.	1.5	46
261	Comparison of Urticaria Activity Score Over 7ÂDays (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study. American Journal of Clinical Dermatology, 2018, 19, 267-274.	6.7	46
262	How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 113-124.	3.8	46
263	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
264	Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria. Allergy, Asthma and Immunology Research, 2021, 13, 545.	2.9	46
265	ASSUREâ€CSU: a realâ€world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. Clinical and Translational Allergy, 2015, 5, 29.	3.2	45
266	Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 869-877.	5.7	45
267	Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2017, 140, 1749-1751.	2.9	45
268	The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. World Allergy Organization Journal, 2018, 11, 5.	3.5	45
269	Antihistamineâ€resistant chronic spontaneous urticaria: 1â€year data from the AWARE study. Clinical and Experimental Allergy, 2019, 49, 655-662.	2.9	45
270	Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema. Clinical and Experimental Dermatology, 2014, 39, 298-303.	1.3	44

#	Article	IF	CITATIONS
271	Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema. Frontiers in Medicine, 2017, 4, 212.	2.6	44
272	Interleukinâ€17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clinical and Experimental Allergy, 2020, 50, 799-804.	2.9	44
273	Intact hair follicle innervation is not essential for anagen induction and development. Archives of Dermatological Research, 1998, 290, 574-578.	1.9	43
274	Hereditary Angioedema with Normal C1 Inhibitor. Immunology and Allergy Clinics of North America, 2017, 37, 571-584.	1.9	43
275	Urticaria and Angioedema Across the Ages. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1866-1874.	3.8	43
276	Histamine and Antihistamines in Atopic Dermatitis. Advances in Experimental Medicine and Biology, 2010, 709, 73-80.	1.6	42
277	Can On-demand Non-sedating Antihistamines Improve Urticaria Symptoms? A Double-blind, Randomized, Single-dose Study. Acta Dermato-Venereologica, 2013, 93, 168-174.	1.3	42
278	<i>F12</i> â€46C/T polymorphism as modifier of the clinical phenotype of hereditary angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1661-1664.	5.7	42
279	Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum <scp>IL</scp> â€31 levels. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 454-455.	2.4	41
280	Efficacy and safety of dupilumab for moderateâ€ŧoâ€severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 45-58.	5.7	41
281	Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1056-1063.	2.4	40
282	Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant. Acta Dermato-Venereologica, 2018, 98, 26-31.	1.3	40
283	Autoimmune Chronic Spontaneous Urticaria Detection with IgG Anti-TPO and Total IgE. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4138-4146.e8.	3.8	40
284	Critical role of IL-10 in the induction of low zone tolerance to contact allergens. Journal of Clinical Investigation, 2003, 112, 432-439.	8.2	40
285	Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. JDDG - Journal of the German Society of Dermatology, 2013, 11, 971-978.	0.8	39
286	Skin and Systemic Inflammation in Schnitzler's Syndrome Are Associated With Neutrophil Extracellular Trap Formation. Frontiers in Immunology, 2019, 10, 546.	4.8	39
287	Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell–Mediated Angioedema. Clinical Reviews in Allergy and Immunology, 2021, 61, 40-49.	6.5	39
288	Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1465-1468.	5.7	38

#	Article	IF	CITATIONS
289	Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria. Journal of Allergy and Clinical Immunology, 2016, 138, 1483-1485.e9.	2.9	38
290	Positive CD63 Basophil Activation Tests Are Common in Children with Chronic Spontaneous Urticaria and Linked to High Disease Activity. International Archives of Allergy and Immunology, 2016, 171, 81-88.	2.1	38
291	Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic. Allergologie Select, 2020, 4, 53-68.	3.1	38
292	Matrix metalloproteinaseâ€9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients?. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 652-656.	5.7	37
293	Modern Approaches to the Diagnosis and Treatment of Cold Contact Urticaria. Current Allergy and Asthma Reports, 2010, 10, 243-249.	5.3	37
294	Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1452-1459.	5.7	37
295	A novel method to generate and culture human mast cells: Peripheral CD34+ stem cell-derived mast cells (PSCMCs). Journal of Immunological Methods, 2014, 413, 62-68.	1.4	37
296	Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals. International Archives of Allergy and Immunology, 2015, 167, 21-28.	2.1	37
297	The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. World Allergy Organization Journal, 2022, 15, 100627.	3.5	37
298	Turkish Version of the Chronic Urticaria Quality of Life Questionnaire: Cultural Adaptation, Assessment of Reliability and Validity. Acta Dermato-Venereologica, 2012, 92, 419-425.	1.3	36
299	Omalizumab substantially improves dermatologyâ€related quality of life in patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1715-1721.	2.4	36
300	Antiâ€KIT monoclonal antibody CDXâ€0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2393-2403.	5.7	36
301	Anaphylaxis caused by mosquito allergy in systemic mastocytosis. Lancet, The, 2013, 382, 1380.	13.7	35
302	Basophilic histamine content and release during venom immunotherapy: Insights by flow cytometry. Cytometry Part B - Clinical Cytometry, 2013, 84B, 173-178.	1.5	35
303	Unexplained recurrent fever: when is autoinflammation the explanation?. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 285-296.	5.7	35
304	A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism. Clinical and Experimental Dermatology, 2013, 38, 360-366.	1.3	35
305	In psoriasis, levels of hope and quality of life are linked. Archives of Dermatological Research, 2014, 306, 661-666.	1.9	35
306	Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria. Acta Dermato-Venereologica, 2016, 96, 56-59.	1.3	35

#	Article	IF	CITATIONS
307	Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion. European Journal of Dermatology, 2017, 27, 10-19.	0.6	35
308	Plateletâ€activating factor (<scp>PAF</scp>) induces wheal and flare skin reactions independent of mast cell degranulation. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 256-258.	5.7	34
309	Disease Activity Only Moderately Correlates with Quality of Life Impairment in Patients with Chronic Spontaneous Urticaria. Dermatology, 2013, 226, 371-379.	2.1	34
310	Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2–11 years. Pediatric Allergy and Immunology, 2016, 27, 55-61.	2.6	34
311	Clinical Measures of Chronic Urticaria. Immunology and Allergy Clinics of North America, 2017, 37, 35-49.	1.9	34
312	Effect of Dietary Fiber and Metabolites on Mast Cell Activation and Mast Cell-Associated Diseases. Frontiers in Immunology, 2018, 9, 1067.	4.8	34
313	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wiener Klinische Wochenschrift, 2012, 124, 807-814.	1.9	33
314	Atopic predisposition in cholinergic urticaria patients and its implications. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 2060-2065.	2.4	33
315	Cardiac safety of secondâ€generation H ₁ â€antihistamines when updosed in chronic spontaneous urticaria. Clinical and Experimental Allergy, 2019, 49, 1615-1623.	2.9	33
316	Antihistamineâ€resistant chronic spontaneous urticaria remains undertreated: 2â€year data from the AWARE study. Clinical and Experimental Allergy, 2020, 50, 1166-1175.	2.9	33
317	Longâ€ŧerm prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 979-990.	5.7	33
318	Calcitonin geneâ€related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria. Clinical and Experimental Allergy, 2014, 44, 1053-1060.	2.9	32
319	Chronic urticaria: tools to aid the diagnosis and assessment of disease status in daily practice. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 38-44.	2.4	32
320	Impact of psoriasis severity on family income and quality of life. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 438-443.	2.4	32
321	Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency. Gene, 2018, 667, 76-82.	2.2	32
322	Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, doubleâ€blind, placebo ontrolled study. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 141-151.	5.7	32
323	Guideline: Hereditary angioedema due to C1 inhibitor deficiency. Allergo Journal International, 2019, 28, 16-29.	2.0	32
324	Pruritus and sleep disturbances in patients with psoriasis. Archives of Dermatological Research, 2020, 312, 103-111.	1.9	32

#	Article	IF	CITATIONS
325	Cold-induced urticarial autoinflammatory syndrome related to factor XII activation. Nature Communications, 2020, 11, 179.	12.8	32
326	Desloratadine Inhibits Human Skin Mast Cell Activation and Histamine Release. Journal of Investigative Dermatology, 2009, 129, 2723-2726.	0.7	31
327	Immature mast cells exhibit rolling and adhesion to endothelial cells and subsequent diapedesis triggered by E―and Pâ€selectin, VCAMâ€1 and PECAMâ€1. Experimental Dermatology, 2010, 19, 424-434.	2.9	31
328	Mast cells in endometriosis: guilty or innocent bystanders?. Expert Opinion on Therapeutic Targets, 2012, 16, 237-241.	3.4	31
329	Intractable Headaches, Ischemic Stroke, and Seizures Are Linked to the Presence of Anti-β2GPI Antibodies in Patients with Systemic Lupus Erythematosus. PLoS ONE, 2015, 10, e0119911.	2.5	31
330	Brain histamine H ₁ receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. Expert Opinion on Drug Safety, 2015, 14, 199-206.	2.4	31
331	Development and validation of the Cholinergic Urticaria Qualityâ€ofâ€Life Questionnaire (CholUâ€QoL). Clinical and Experimental Allergy, 2018, 48, 433-444.	2.9	31
332	Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The <scp>OPuS</scp> â€2Âstudy. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1871-1880.	5.7	31
333	T cell killing by tolerogenic dendritic cells protects mice from allergy. Journal of Clinical Investigation, 2011, 121, 3860-3871.	8.2	31
334	Cold Urticaria Patients Exhibit Normal Skin Levels of Functional Mast Cells and Histamine after Tolerance Induction. Dermatology, 2012, 224, 101-105.	2.1	30
335	Effects of omalizumab in a patient with three types of chronic urticaria. British Journal of Dermatology, 2014, 170, 469-471.	1.5	30
336	Murine and human mast cell progenitors. European Journal of Pharmacology, 2016, 778, 2-10.	3.5	30
337	Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organization Journal, 2018, 11, 32.	3.5	30
338	Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. World Allergy Organization Journal, 2020, 13, 100460.	3.5	30
339	Novel Insights on MRGPRX2-Mediated Hypersensitivity to Neuromuscular Blocking Agents And Fluoroquinolones. Frontiers in Immunology, 2021, 12, 668962.	4.8	30
340	Hair growth control by immunosuppression. Archives of Dermatological Research, 1996, 288, 408-410.	1.9	29
341	Issues and Personalities in German and Dutch Television News. European Journal of Communication, 2001, 16, 337-359.	1.4	29
342	Neurotrophin-3 regulates mast cell functions in neonatal mouse skin. Experimental Dermatology, 2004, 13, 273-281.	2.9	29

#	Article	IF	CITATIONS
343	Selected urticaria patients benefit from a referral to tertiary care centres – results of an expert survey. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e8-16.	2.4	29
344	Histamine, TNF, C5a, IL-6, -9, -18, -31, -33, TSLP, Neopterin, and VEGF are not elevated in chronic spontaneous urticaria. Journal of Dermatological Science, 2013, 70, 222-225.	1.9	29
345	Chronic idiopathic urticaria (CIU) is no longer idiopathic: time for an update. British Journal of Dermatology, 2013, 168, 455-456.	1.5	29
346	Activation of the Prostaglandin E2 receptor <scp>EP</scp> 2 prevents house dust miteâ€induced airway hyperresponsiveness and inflammation by restraining mast cells' activity. Clinical and Experimental Allergy, 2015, 45, 1590-1600.	2.9	29
347	Histamine intolerance in patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1774-1777.	2.4	29
348	Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey. Clinical and Translational Allergy, 2018, 8, 42.	3.2	29
349	Definition, aims, and implementation of GA ² LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2115-2123.	5.7	29
350	The majority of brain mast cells in B10.PL mice is present in the hippocampal formation. Neuroscience Letters, 2006, 392, 174-177.	2.1	28
351	Adaptation and initial results of the Polish version of the GA2LEN Chronic Urticaria Quality Of Life Questionnaire (CU-Q2oL). Journal of Dermatological Science, 2011, 62, 36-41.	1.9	28
352	Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies. World Allergy Organization Journal, 2011, 4, S9-S21.	3.5	28
353	Longâ€ŧerm prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. JDDG - Journal of the German Society of Dermatology, 2011, 9, 99-107.	0.8	28
354	Polidocanol inhibits cowhage ―but not histamineâ€induced itch in humans. Experimental Dermatology, 2014, 23, 922-923.	2.9	28
355	Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey. Clinical and Experimental Immunology, 2017, 188, 148-153.	2.6	28
356	Genetic Determinants of C1 Inhibitor Deficiency Angioedema Age of Onset. International Archives of Allergy and Immunology, 2017, 174, 200-204.	2.1	28
357	Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings, 2017, 38, 143-151.	2.2	28
358	Management of chronic spontaneous urticaria: a worldwide perspective. World Allergy Organization Journal, 2018, 11, 14.	3.5	28
359	MRGPRX2 and Immediate Drug Hypersensitivity: Insights From Cultured Human Mast Cells. Journal of Investigational Allergology and Clinical Immunology, 2021, 31, 489-499.	1.3	28
360	Impact of lanadelumab on healthâ€related quality of life in patients with hereditary angioedema in the HELP study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1188-1198.	5.7	28

#	Article	IF	CITATIONS
361	The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. Journal of the American Academy of Dermatology, 2021, 84, 691-700.	1.2	28
362	Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immuneâ€mediated dermatological conditions. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2355-2366.	5.7	28
363	Mast cells protect from skin tumor development and limit tumor growth during cutaneous <i>de novo</i> carcinogenesis in a <scp>K</scp> itâ€dependent mouse model. Experimental Dermatology, 2014, 23, 159-164.	2.9	27
364	Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 220-226.	2.3	27
365	Treatments of cold urticaria: AÂsystematic review. Journal of Allergy and Clinical Immunology, 2019, 143, 1311-1331.	2.9	27
366	Consensus on treatment goals in hereditary angioedema: AÂglobal Delphi initiative. Journal of Allergy and Clinical Immunology, 2021, 148, 1526-1532.	2.9	27
367	What is the contribution of IgE to nasal polyposis?. Journal of Allergy and Clinical Immunology, 2021, 147, 1997-2008.	2.9	27
368	A Role for Bax in the Regulation of Apoptosis in Mouse Mast Cells. Journal of Investigative Dermatology, 2000, 114, 1205-1206.	0.7	26
369	What determines the success or failure of intracellular cutaneous parasites? Lessons learned from leishmaniasis. Medical Microbiology and Immunology, 2009, 198, 137-146.	4.8	26
370	Miltefosine Inhibits Human Mast Cell Activation and Mediator Release Both In Vitro and In Vivo. Journal of Investigative Dermatology, 2009, 129, 496-498.	0.7	26
371	Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies. World Allergy Organization Journal, 2011, 4, S9-S21.	3.5	26
372	H ₁ â€antihistamines and urticaria: how can we predict the best drug for our patient?. Clinical and Experimental Allergy, 2012, 42, 1423-1429.	2.9	26
373	Omalizumab for Chronic Urticaria. New England Journal of Medicine, 2013, 368, 2527-2530.	27.0	26
374	Neues von der internationalen Leitlinie für Diagnostik und Therapie der chronischen Urtikaria. JDDG - Journal of the German Society of Dermatology, 2013, 11, 971-979.	0.8	26
375	Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Annals of Allergy, Asthma and Immunology, 2016, 117, 370-377.e1.	1.0	26
376	Safeguarding of Fetal Growth by Mast Cells and Natural Killer Cells: Deficiency of One Is Counterbalanced by the Other. Frontiers in Immunology, 2017, 8, 711.	4.8	26
377	In chronic spontaneous urticaria, IgE against staphylococcal enterotoxins is common and functional. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1497-1504.	5.7	26
378	Diagnosis and treatment of chronic inducible urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2550-2553.	5.7	26

#	Article	IF	CITATIONS
379	Skin microdialysis: methods, applications and future opportunities—an EAACI position paper. Clinical and Translational Allergy, 2019, 9, 24.	3.2	26
380	Management of urticarial vasculitis: A worldwide physician perspective. World Allergy Organization Journal, 2020, 13, 100107.	3.5	26
381	Urticaria. Deutsches Ärzteblatt International, 2008, 105, 458-65; quiz 465-6.	0.9	26
382	Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A oneâ€year extension study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2175-2184.	5.7	26
383	Selected recent advances in understanding the role of human mast cells in health and disease. Journal of Allergy and Clinical Immunology, 2022, 149, 1833-1844.	2.9	26
384	Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo. Journal of Allergy and Clinical Immunology, 2022, 149, 1998-2009.e5.	2.9	26
385	Patients with chronic urticaria exhibit increased rates of sensitisation to <i>Candida albicans</i> , but not to common moulds. Mycoses, 2009, 52, 334-338.	4.0	25
386	Prophylaxis of hereditary angioedema attacks: AÂrandomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology, 2016, 138, 934-936.e5.	2.9	25
387	Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review. Acta Dermato-Venereologica, 2019, 99, 905-906.	1.3	25
388	Real-life treatment of cholinergic urticaria with omalizumab. Journal of Allergy and Clinical Immunology, 2019, 143, 788-791.e8.	2.9	25
389	Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2879-2887.	5.7	25
390	Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome. Journal of Allergy and Clinical Immunology, 2020, 145, 1681-1686.e5.	2.9	25
391	Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: results of a large cross-sectional study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2012, 106, 137-142.	1.8	24
392	Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed firstâ€line treatments. International Journal of Dermatology, 2015, 54, 1088-1104.	1.0	24
393	Cholinergic urticaria patients of different age groups have distinct features. Clinical and Experimental Allergy, 2017, 47, 1609-1614.	2.9	24
394	Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change. Health and Quality of Life Outcomes, 2019, 17, 160.	2.4	24
395	Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions. Journal of Allergy and Clinical Immunology, 2019, 144, S19-S30.	2.9	24
396	EAACI Biologicals Guidelines—dupilumab for children and adults with moderateâ€ŧoâ€severe atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 988-1009.	5.7	24

#	Article	IF	CITATIONS
397	Safety and Efficacy of Desloratadine in Subjects with Seasonal Allergic Rhinitis or Chronic Urticaria. Clinical Drug Investigation, 2010, 30, 109-122.	2.2	23
398	Rupatadine for the treatment of allergic rhinitis and urticaria. Expert Review of Clinical Immunology, 2011, 7, 15-20.	3.0	23
399	Randomized, doubleâ€blind, placeboâ€controlled study of safety and efficacy of miltefosine in antihistamineâ€resistant chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e363-9.	2.4	23
400	Use of skin biomarker profiles to distinguish Schnitzler syndrome from chronic spontaneous urticaria: results of a pilot study. British Journal of Dermatology, 2018, 178, 561-562.	1.5	23
401	Comorbidity of viral hepatitis and chronic spontaneous urticaria: A systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1946-1953.	5.7	23
402	Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 468-470.	5.7	23
403	Sexual Functioning Is Frequently and Markedly Impaired in Female Patients with Chronic Spontaneous Urticaria. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1074-1082.	3.8	23
404	Who is really in control of skin immunity underphysiologicalcircumstances - lymphocytes, dendritic cells or keratinocytes?. Experimental Dermatology, 2006, 15, 913-929.	2.9	23
405	Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA. Allergologie Select, 2020, 4, 44-52.	3.1	23
406	Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 91-99.	2.4	23
407	Phenotypical characterization of c-kit receptor deficient mouse femora using non-destructive high-resolution imaging techniques and biomechanical testing. Technology and Health Care, 2000, 8, 267-275.	1.2	22
408	Mast cells determine the magnitude of bacterial toxinâ€induced skin inflammation. Experimental Dermatology, 2009, 18, 160-166.	2.9	22
409	Chronic Spontaneous Urticaria: How to Assess Quality of Life in Patients Receiving Treatment. Archives of Dermatology, 2011, 147, 1221.	1.4	22
410	Adaptación transcultural del cuestionario Urticaria Control Test del alemán al castellano. Actas Dermo-sifiliográficas, 2015, 106, 746-752.	0.4	22
411	Questions and answers in chronic urticaria: where do we stand and where do we go?. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 7-15.	2.4	22
412	Ultraviolet radiation and skin mast cells: Effects, mechanisms and relevance for skin diseases. Experimental Dermatology, 2018, 27, 3-8.	2.9	22
413	Human Mast Cell Tryptase Is a Potential Treatment for Snakebite Envenoming Across Multiple Snake Species. Frontiers in Immunology, 2018, 9, 1532.	4.8	22
414	Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A realâ€life study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2073-2075.	5.7	22

#	Article	IF	CITATIONS
415	Validation of the Turkish version of the Urticaria Control Test: Correlation with other tools and comparison between spontaneous and inducible chronic urticaria. World Allergy Organization Journal, 2019, 12, 100009.	3.5	22
416	How to discontinue omalizumab in chronic spontaneous urticaria?. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 821-824.	5.7	22
417	Longâ€ŧerm safety and effectiveness of berotralstat for hereditary angioedema: The openâ€label APeXâ€& study. Clinical and Translational Allergy, 2021, 11, e12035.	3.2	22
418	Hair growthâ€modulation by adrenergic drugs. Experimental Dermatology, 1999, 8, 274-281.	2.9	21
419	Update on chronic urticaria: focusing on mechanisms. Current Opinion in Allergy and Clinical Immunology, 2008, 8, 433-437.	2.3	21
420	Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clinical and Experimental Dermatology, 2009, 34, e137-e140.	1.3	21
421	Longâ€ŧerm reduction in local inflammation by a lipid raft molecule in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1158-1165.	5.7	21
422	A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 665-670.	5.7	21
423	Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 119-120.	2.4	21
424	Inflammatory skin responses induced by icatibant injection are mast cell mediated and attenuated by H ₁ â€antihistamines. Experimental Dermatology, 2012, 21, 154-155.	2.9	21
425	Cardioprotective C-kit+ Bone Marrow Cells Attenuate Apoptosis after Acute Myocardial Infarction in Mice - In-vivo Assessment with Fluorescence Molecular Imaging. Theranostics, 2013, 3, 903-913.	10.0	21
426	Lactic acid sting test does not differentiate between facial and generalized skin functional impairment in sensitive skin in atopic dermatitis and rosacea. Journal of Dermatological Science, 2014, 76, 151-153.	1.9	21
427	Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT). Health and Quality of Life Outcomes, 2016, 14, 61.	2.4	21
428	The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1214-1222.	2.4	21
429	In vivo non-invasive staining-free visualization of dermal mast cells in healthy, allergy and mastocytosis humans using two-photon fluorescence lifetime imaging. Scientific Reports, 2020, 10, 14930.	3.3	21
430	The Diagnostic Workup in Chronic Spontaneous Urticaria—What to Test and Why. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2274-2283.	3.8	21
431	What Basophil Testing Tells Us About CSU Patients – Results of the CORSA Study. Frontiers in Immunology, 2021, 12, 742470.	4.8	21
432	Proposal of 0.5Âmg of protein/100Âg of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1736-1750.	5.7	21

#	Article	IF	CITATIONS
433	Activated skin mast cells are involved in murine hair follicle regression (catagen). Laboratory Investigation, 1997, 77, 319-32.	3.7	21
434	Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways. Journal of Biological Regulators and Homeostatic Agents, 2014, 28, 575-85.	0.7	21
435	Does allergy impair innate immunity? Leads and lessons from atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1351-1356.	5.7	20
436	The status quo and unmet needs in the management of allergic rhinitis and chronic rhinosinusitis: a Malaysian perspective. Asia Pacific Allergy, 2014, 4, 142-148.	1.3	20
437	Omalizumab for the treatment of chronic urticaria. Expert Review of Clinical Immunology, 2015, 11, 171-180.	3.0	20
438	Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies. Health and Quality of Life Outcomes, 2015, 13, 92.	2.4	20
439	Immunological effects and potential mechanisms of action of autologous serum therapy in chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1747-1754.	2.4	20
440	On the Lipophilic Nature of Autoreactive IgE in Chronic Spontaneous Urticaria. Theranostics, 2019, 9, 829-836.	10.0	20
441	The complex role of mast cells in fungal infections. Experimental Dermatology, 2019, 28, 749-755.	2.9	20
442	Rapid identification of human mast cell degranulation regulators using functional genomics coupled to high-resolution confocal microscopy. Nature Protocols, 2020, 15, 1285-1310.	12.0	20
443	Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies. World Allergy Organization Journal, 2011, 4, S9.	3.5	20
444	Risk factors for systemic reactions in typical cold urticaria: Results from the COLD E study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2185-2199.	5.7	20
445	Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. British Journal of Dermatology, 2010, 162, 185-190.	1.5	19
446	Analysis of characteristics associated with reinjection of icatibant: Results from the Icatibant Outcome Survey. Allergy and Asthma Proceedings, 2015, 36, 399-406.	2.2	19
447	Patients with chronic cold urticaria may benefit from doxycycline therapy. British Journal of Dermatology, 2017, 176, 259-261.	1.5	19
448	Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e413-e415.	2.4	19
449	A novel deep intronic SERPING1 variant as a cause of hereditary angioedema due to C1-inhibitor deficiency. Allergology International, 2020, 69, 443-449.	3.3	19
450	Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both. World Allergy Organization Journal, 2021, 14, 100501.	3.5	19

#	Article	IF	CITATIONS
451	EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17Âyears old. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 17-38.	5.7	19
452	Beyond flat weals: validation of a three-dimensional imaging technology that will improve skin allergy research. Clinical and Experimental Dermatology, 2008, 33, 772-775.	1.3	18
453	Treatment of notalgia paraesthetica with an 8% capsaicin patch. British Journal of Dermatology, 2011, 165, 1359-1361.	1.5	18
454	Langzeitprophylaxe des hereditäen Angioödems mit Androgenderivaten: kritische Bewertung und mögliche Alternativen. JDDG - Journal of the German Society of Dermatology, 2011, 9, 99-108.	0.8	18
455	Treatment of hereditary angioedema with icatibant: Efficacy in clinical trials versus effectiveness in the real-world setting. Allergy and Asthma Proceedings, 2014, 35, 377-381.	2.2	18
456	Membraneâ€bound stem cell factor is the major but not only driver of fibroblastâ€induced murine skin mast cell differentiation. Experimental Dermatology, 2017, 26, 255-262.	2.9	18
457	Chronic Urticaria in Children. JAMA Dermatology, 2017, 153, 1221.	4.1	18
458	Association of CCL2 with systemic inflammation in Schnitzler syndrome. British Journal of Dermatology, 2019, 180, 859-868.	1.5	18
459	A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticaria. Clinical and Translational Allergy, 2021, 11, e12031.	3.2	18
460	Diagnosis of urticaria. Indian Journal of Dermatology, 2013, 58, 211.	0.3	18
461	Effects of Antihistamines on Innate Immune Responses to Severe Bacterial Infection in Mice. International Archives of Allergy and Immunology, 2011, 155, 355-360.	2.1	17
462	Effective Control of Recalcitrant Pruritus by Bevacizumab: A Possible Role for Vascular Endothelial Growth Factor in Chronic Itch?. Acta Dermato-Venereologica, 2013, 93, 175-179.	1.3	17
463	Skin provocation tests may help to diagnose atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1745-1752.	5.7	17
464	Development and validation of the mastocytosis activity score. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1489-1496.	5.7	17
465	In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are linked to recurrent angio-oedema. Clinical and Experimental Dermatology, 2018, 43, 131-136.	1.3	17
466	Chronic urticaria – What does the new guideline tell us?. JDDG - Journal of the German Society of Dermatology, 2018, 16, 584-593.	0.8	17
467	The Henna pigment Lawsone activates the Aryl Hydrocarbon Receptor and impacts skin homeostasis. Scientific Reports, 2019, 9, 10878.	3.3	17
468	Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3744-3751.	3.8	17

#	Article	IF	CITATIONS
469	Hereditary angioedema: an update on available therapeutic options. JDDG - Journal of the German Society of Dermatology, 2010, 8, 663-672.	0.8	16
470	Mast cells cultured from IL-3-treated mice show impaired responses to bacterial antigen stimulation. Inflammation Research, 2012, 61, 79-85.	4.0	16
471	The effects of Fasciola hepatica tegumental antigens on mast cell function. International Journal for Parasitology, 2013, 43, 531-539.	3.1	16
472	Chronic spontaneous urticaria $\hat{a} \in $ a management pathway for patients with chronic spontaneous urticaria. JDDG - Journal of the German Society of Dermatology, 2015, 13, 419-428.	0.8	16
473	Omalizumab may not inhibit mast cell and basophil activation <i>in vitro</i> . Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1832-1836.	2.4	16
474	Longâ€ŧerm safety of icatibant treatment of patients with angioedema in realâ€world clinical practice. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 994-998.	5.7	16
475	Chronic urticaria can be caused by cancer and resolves with its cure. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1562-1566.	5.7	16
476	Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients. BioMed Research International, 2019, 2019, 1-4.	1.9	16
477	A mutation in the kringle domain of human factor XII that causes autoinflammation, disturbs zymogen quiescence, and accelerates activation. Journal of Biological Chemistry, 2020, 295, 363-374.	3.4	16
478	The Chronic Urticaria Registry: rationale, methods and initial implementation. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 721-729.	2.4	16
479	Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema. Clinical Reviews in Allergy and Immunology, 2021, 61, 84-97.	6.5	16
480	Spleen tyrosine kinase inhibition blocks airway constriction and protects from Th2â€induced airway inflammation and remodeling. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1061-1072.	5.7	15
481	Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador. World Allergy Organization Journal, 2017, 10, 21.	3.5	15
482	Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer. New England Journal of Medicine, 2018, 379, 2176-2177.	27.0	15
483	State of care for patients with systemic autoinflammatory diseases – Results of a tertiary care survey. World Allergy Organization Journal, 2019, 12, 100019.	3.5	15
484	Disease activity and stress are linked in a subpopulation of chronic spontaneous urticaria patients. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 224-226.	5.7	15
485	Omalizumab in chronic inducible urticaria: A realâ€life study of efficacy, safety, predictors of treatment outcome and time to response. Clinical and Experimental Allergy, 2021, 51, 730-734.	2.9	15
486	Lower IgA Levels in Chronic Spontaneous Urticaria Are Associated With Lower IgE Levels and Autoimmunity. Frontiers in Immunology, 2021, 12, 657211.	4.8	15

#	Article	IF	CITATIONS
487	Effects of pregnancy on chronic urticaria: Results of the PREG U UCARE study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3133-3144.	5.7	15
488	Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised doubleâ€blind placebo ontrolled study. British Journal of Clinical Pharmacology, 2021, 87, 4797-4808.	2.4	15
489	Prevalence and factors associated with sleep disturbance in adult patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 688-697.	2.4	15
490	Use of topical steroids is largely restricted by irrational emotional concerns in both patients and physicians. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1560-1561.	5.7	14
491	HereditÃæs Angioödem: Update zu verfügbaren Therapieoptionen. JDDG - Journal of the German Society of Dermatology, 2010, 8, 663-673.	0.8	14
492	Urticarial Vasculitis and Schnitzler Syndrome. Immunology and Allergy Clinics of North America, 2014, 34, 141-147.	1.9	14
493	Successful treatment of cholinergic urticaria with methantheliniumbromide. Journal of Dermatology, 2015, 42, 422-424.	1.2	14
494	Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey. Allergy, Asthma and Clinical Immunology, 2017, 13, 31.	2.0	14
495	Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2998-3016.	5.7	14
496	Topical inflammasome inhibition with disulfiram prevents irritant contact dermatitis. Clinical and Translational Allergy, 2021, 11, e12045.	3.2	14
497	Costâ€intensive, timeâ€consuming, problematical? How physicians in private practice experience the care of urticaria patients. JDDG - Journal of the German Society of Dermatology, 2012, 10, 341-347.	0.8	13
498	An internet survey on selfâ€reported food allergy in Greece: clinical aspects and lack of appropriate medical consultation. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 558-564.	2.4	13
499	Pharmacotherapy of chronic spontaneous urticaria. Expert Opinion on Pharmacotherapy, 2013, 14, 2511-2519.	1.8	13
500	The Inhibition by Levocetirizine and Fexofenadine of the Histamine-induced Wheal and Flare Response in Healthy Caucasian and Japanese Volunteers. Acta Dermato-Venereologica, 2013, 93, 286-293.	1.3	13
501	H ₁ â€Antihistamines and itch in atopic dermatitis. Experimental Dermatology, 2015, 24, 332-333.	2.9	13
502	Allergen-loaded strontium-doped hydroxyapatite spheres improve allergen-specific immunotherapy in mice. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 570-578.	5.7	13
503	Expert consensus on practical aspects in the treatment of chronic urticaria. Allergo Journal International, 2021, 30, 64-75.	2.0	13
504	The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study. World Allergy Organization Journal, 2020, 13, 100475.	3.5	13

#	Article	IF	CITATIONS
505	Kostenintensiv, zeitaufwendig, problematisch? - Die Betreuung von Urtikariapatienten aus der Perspektive niedergelassener A…rzte. JDDG - Journal of the German Society of Dermatology, 2012, 10, 341-349.	0.8	12
506	Antihistamines. Chemical Immunology and Allergy, 2014, 100, 302-310.	1.7	12
507	Cross-Cultural Adaptation of the Urticaria Control Test From German to Castilian Spanish. Actas Dermo-sifiliográficas, 2015, 106, 746-752.	0.4	12
508	Mast cells: Promoters of health and modulators of disease. Journal of Allergy and Clinical Immunology, 2019, 144, S1-S3.	2.9	12
509	Vibratory Angioedema Subgroups, Features, and Treatment: Results of a Systematic Review. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 971-984.	3.8	12
510	Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema. World Allergy Organization Journal, 2021, 14, 100554.	3.5	12
511	Idiopathic mast cell activation syndrome is more often suspected than diagnosed—A prospective realâ€life study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2794-2802.	5.7	12
512	Urticaria crónica: estudio etiológico prospectivo e importancia del sÃndrome autoinmune. Actas Dermo-sifiliográficas, 2004, 95, 560-566.	0.4	11
513	Treatment strategies in urticaria. Expert Opinion on Pharmacotherapy, 2010, 11, 1445-1450.	1.8	11
514	Evidence that the endothelin AÂreceptor can enhance IgE-dependent anaphylaxis in mice. Journal of Allergy and Clinical Immunology, 2011, 128, 424-426.e1.	2.9	11
515	Innate Immunity in Atopic Dermatitis. Current Problems in Dermatology, 2011, 41, 104-111.	0.7	11
516	Immunoregulation in cutaneous allergy. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 498-503.	2.3	11
517	The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Przeglad Dermatologiczny, 2015, 2, 155-179.	0.1	11
518	Comparison of applied dose and image quality in staging CT of neuroendocrine tumor patients using standard filtered back projection and adaptive statistical iterative reconstruction. European Journal of Radiology, 2015, 84, 1601-1607.	2.6	11
519	Increased angiogenesis and <scp>VEGF</scp> expression correlates with disease severity in prurigo patients. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1357-1361.	2.4	11
520	A simulated carâ€driving study on the effects of acute administration of levocetirizine, fexofenadine, and diphenhydramine in healthy Japanese volunteers. Human Psychopharmacology, 2016, 31, 167-177.	1.5	11
521	Chronic urticaria in most patients is poorly controlled. Journal of King Abdulaziz University, Islamic Economics, 2017, 38, 1230-1236.	1.1	11
522	Mast cells are critical for the limitation of thrombinâ€induced skin inflammation. Experimental Dermatology, 2018, 27, 50-57.	2.9	11

#	Article	IF	CITATIONS
523	Angioedema frequently occurs in cholinergic urticaria. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1355-1357.e1.	3.8	11
524	Skin Mast Cells Contribute to Sporothrix schenckii Infection. Frontiers in Immunology, 2020, 11, 469.	4.8	11
525	Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2486-2489.e4.	3.8	11
526	Mast Cells Modulate Antigen-Specific CD8+ T Cell Activation During LCMV Infection. Frontiers in Immunology, 2021, 12, 688347.	4.8	11
527	How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. World Allergy Organization Journal, 2021, 14, 100542.	3.5	11
528	Miltefosine: a novel treatment option for mast cell-mediated diseases. Journal of Dermatological Treatment, 2013, 24, 244-249.	2.2	10
529	Urticaria and Angioedema. Chemical Immunology and Allergy, 2014, 100, 101-104.	1.7	10
530	Galactose-α-1,3-Galactose Allergy Is Not a Hitherto Unrecognized Cause of Chronic Spontaneous Urticaria. International Archives of Allergy and Immunology, 2015, 167, 250-252.	2.1	10
531	Serum neuron specific enolase $\hat{a} \in \hat{a}$ a novel indicator for neuropsychiatric systemic lupus erythematosus?. Lupus, 2015, 24, 1492-1497.	1.6	10
532	Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings, 2016, 37, 489-500.	2.2	10
533	Seasonal Exacerbation of Asthma Is Frequently Associated with Recurrent Episodes of Acute Urticaria. International Archives of Allergy and Immunology, 2016, 169, 263-266.	2.1	10
534	Current and future therapies for treating chronic spontaneous urticaria. Expert Opinion on Pharmacotherapy, 2016, 17, 1131-1139.	1.8	10
535	Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey. Clinical and Translational Allergy, 2019, 9, 37.	3.2	10
536	Minimal important difference of the Chronic Urticaria Quality of Life Questionnaire (CUâ€Q2oL). Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2542-2544.	5.7	10
537	Realâ€life treatment of patients with cholinergic urticaria in Germanâ€speaking countries. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1141-1147.	0.8	10
538	T helper 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of inducible Tâ€cell costimulator. British Journal of Dermatology, 2020, 182, 648-657.	1.5	10
539	Delayed Pressure Urticaria: A Systematic Review of Treatment Options. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2035-2049.e5.	3.8	10
540	Omalizumab in children and adolescents with chronic urticaria: A 16â€week realâ€world study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1271-1273.	5.7	10

#	Article	IF	CITATIONS
541	Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?. Allergologie Select, 2021, 5, 89-95.	3.1	10
542	Cold Agglutinins and Cryoglobulins Associate With Clinical and Laboratory Parameters of Cold Urticaria. Frontiers in Immunology, 2021, 12, 665491.	4.8	10
543	Anaphylaxis to Mepolizumab and Omalizumab in a Single Patient: Is Polysorbate the Culprit?. Journal of Investigational Allergology and Clinical Immunology, 2020, 30, 285-287.	1.3	10
544	Expert consensus on the use of omalizumab in chronic urticaria in China. World Allergy Organization Journal, 2021, 14, 100610.	3.5	10
545	Urticaria in Pregnancy and Lactation. Frontiers in Allergy, 0, 3, .	2.8	10
546	Anxiety and depression seem less common in patients with autoreactive chronic spontaneous urticaria. Clinical and Experimental Dermatology, 2013, 38, 870-873.	1.3	9
547	Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial. Dermatology and Therapy, 2015, 5, 217-230.	3.0	9
548	Subcutaneous self-injections of C1 inhibitor: an effective and safe treatment in a patient with hereditary angio-oedema. Clinical and Experimental Dermatology, 2016, 41, 91-93.	1.3	9
549	The male beard hair and facial skin – challenges for shaving. International Journal of Cosmetic Science, 2016, 38, 3-9.	2.6	9
550	Alternative treatments for chronic spontaneous urticaria beyond the guideline algorithm. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 278-285.	2.3	9
551	Chymase-Cre; Mcl-1fl/fl Mice Exhibit Reduced Numbers of Mucosal Mast Cells. Frontiers in Immunology, 2019, 10, 2399.	4.8	9
552	The response to treatment in chronic spontaneous urticaria depends on how it is measured. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2055-2056.e4.	3.8	9
553	How to control recurrent angioedema using monoclonal antibody therapies?. Expert Opinion on Biological Therapy, 2020, 20, 1-4.	3.1	9
554	Symptomatic Dermographism: A Systematic Review of Treatment Options. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3141-3161.	3.8	9
555	Response of omalizumab in normocomplementemic urticarial vasculitis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2114-2117.e2.	3.8	9
556	Severe cold urticaria can point to an underlying clonal mast cell disorder. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2609-2613.	5.7	9
557	Peripheral blood cultured mast cells: Phenotypic and functional outcomes of different culture protocols. Journal of Immunological Methods, 2021, 492, 113003.	1.4	9
558	A novel approach for studying mast cell–driven disorders: Mast cells derived from induced pluripotent stem cells. Journal of Allergy and Clinical Immunology, 2022, 149, 1060-1068.e4.	2.9	9

#	Article	IF	CITATIONS
559	Sleep disturbance in adult dermatologic patients: A cross-sectional study on prevalence, burden, and associated factors. Journal of the American Academy of Dermatology, 2021, 85, 910-922.	1.2	9
560	Anwendung von Biologika bei allergischen und Typ-2- entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie – ein Positionspapier von AeDA, DGAKI, GPA, ÖGAI, LGAI, A–GP, ARIA und EAACI. Allergologie, 2020, 43, 255-271.	0.1	9
561	Identification of chronic urticaria subtypes using machine learning algorithms. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 323-326.	5.7	9
562	The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update. Handbook of Experimental Pharmacology, 2021, 268, 117-133.	1.8	9
563	Experienceâ€based advice on stepping up and stepping down the therapeutic management of chronic spontaneous urticaria: Where is the guidance?. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1626-1630.	5.7	9
564	Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria. Clinical and Translational Allergy, 2022, 12, e12121.	3.2	9
565	Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis. Clinical and Translational Allergy, 2021, 11, e12089.	3.2	9
566	What are the most promising strategies for the therapeutic immunomodulation of allergic diseases?Note. Experimental Dermatology, 2001, 10, 128-140.	2.9	8
567	Lack of significant skin inflammation during elimination by apoptosis of large numbers of mouse cutaneous mast cells after cessation of treatment with stem cell factor. Laboratory Investigation, 2004, 84, 1593-1602.	3.7	8
568	Skin Site Mast Cell Numbers Correlate with Rates of Nodular Growth, but Not Incidence, of Basal Cell Carcinoma. Dermatology, 2005, 211, 298-299.	2.1	8
569	Evaluation of the Immunogenicity of the Synthetic α-Melanocyte-Stimulating Hormone (α-MSH) Analogue Afamelanotide ([Nle4- <smlcap>D</smlcap> -Phe7]-α-MSH, Scenesse®) in Erythropoietic Protoporphyria Patients by ELISA Detecting Both Anti-Afamelanotide and Anti-α-MSH Antibodies. Skin Pharmacology and Physiology, 2015, 28, 103-113.	2.5	8
570	Treatment of Severely Recalcitrant Chronic Spontaneous Urticaria: A Discussion of Relevant Issues. American Journal of Clinical Dermatology, 2015, 16, 19-26.	6.7	8
571	Alterations in Hair Follicle Morphology and Hair Shaft Production After Follicular Unit Transplantation. American Journal of Dermatopathology, 2016, 38, 732-738.	0.6	8
572	What we know (and don't know) about the biology and functions of mast cells and basophils. Immunological Reviews, 2018, 282, 5-7.	6.0	8
573	First detection of <i>Leishmania donovani</i> in sand flies from Cameroon and its epidemiological implications. Tropical Medicine and International Health, 2018, 23, 1014-1021.	2.3	8
574	Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1610-1618.e4.	3.8	8
575	P152 CLINICAL ACTIVITY OF AK002, AN ANTI-SIGLEC-8 ANTIBODY, IN MULTIPLE FORMS OF UNCONTROLLED CHRONIC URTICARIA. Annals of Allergy, Asthma and Immunology, 2019, 123, S27-S28.	1.0	8
576	Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 163-169.	2.4	8

#	Article	IF	CITATIONS
577	In Chronic Spontaneous Urticaria, Comorbid Depression Linked to Higher Disease Activity, and Substance P Levels. Frontiers in Psychiatry, 2021, 12, 667978.	2.6	8
578	Automatic screening of selfâ€evaluation apps for urticaria and angioedema shows a high unmet need. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3810-3813.	5.7	8
579	A comprehensive, triâ€national, crossâ€sectional analysis of characteristics and impact of pruritus in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2064-2075.	2.4	8
580	Erfolgreiche Behandlung des hereditäen Angioödems mit dem Bradykinin-B2-Rezeptor-Antagonisten Icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.	0.8	7
581	Can Internet surveys help us understanding allergic disorders? – results from a large survey in urticaria in Greece. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 532-537.	2.4	7
582	Prevalence of nonspecific cutaneous vascular lesions and association with antiphospholipid antibodies in patients with systemic lupus erythematosus. British Journal of Dermatology, 2013, 168, 213-215.	1.5	7
583	Work Productivity and Activity Impairment Among Chronic Spontaneous/Idiopathic Urticaria Patients: ResultsFrom The First International Burden of Illness Study (Assure-Csu). Value in Health, 2015, 18, A427.	0.3	7
584	The Icatibant Outcome Survey. European Journal of Emergency Medicine, 2016, 23, 224-227.	1.1	7
585	Comparison of pruritus and sensory qualities induced by capsaicin, histamine and cowhage. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1755-1761.	2.4	7
586	Inventory and taxonomy of phlebotomine sand flies of the Mokolo leishmaniasis focus, northern Cameroon, with description of new Sergentomyia taxa (Diptera: Psychodidae). Acta Tropica, 2019, 194, 172-180.	2.0	7
587	Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America. World Allergy Organization Journal, 2019, 12, 100011.	3.5	7
588	Sensitization against skin resident fungi is associated with atopy in cholinergic urticaria patients. Clinical and Translational Allergy, 2020, 10, 18.	3.2	7
589	Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy. Frontiers in Immunology, 2021, 12, 652973.	4.8	7
590	Autologous serum skin test reactions in chronic spontaneous urticaria differ from heterologous cell reactions. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1338-1345.	2.4	7
591	Cryoglobulins, Cryofibrinogens, and Cold Agglutinins in Cold Urticaria: Literature Review, Retrospective Patient Analysis, and Observational Study in 49 Patients. Frontiers in Immunology, 2021, 12, 675451.	4.8	7
592	Hair growth control by immunosuppression. Archives of Dermatological Research, 1996, 288, 408-410.	1.9	7
593	Evidence for Non-Allergic Mast Cell Activation in Pollen-Associated Inflammation. Journal of Investigative Dermatology, 2011, 131, 987-990.	0.7	6
594	Innovative approaches to avoid electric shavingâ€induced skin irritation. International Journal of Cosmetic Science, 2016, 38, 10-16.	2.6	6

#	Article	IF	CITATIONS
595	OR034 Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma and Immunology, 2017, 119, S5.	1.0	6
596	Reply. Journal of Allergy and Clinical Immunology, 2018, 141, 1166-1167.	2.9	6
597	Chronische Urtikaria – Was bringt die neue Leitlinie?. JDDG - Journal of the German Society of Dermatology, 2018, 16, 585-595.	0.8	6
598	Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria. European Journal of Dermatology, 2020, 30, 259-266.	0.6	6
599	Effective treatment with mepolizumab in a patient with refractory Wells syndrome. JDDG - Journal of the German Society of Dermatology, 2020, 18, 737-739.	0.8	6
600	Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis. Blood, 2020, 136, 41-42.	1.4	6
601	Instrumente zur Erfassung von Krankheitsaktivitä Krankheitskontrolle und Lebensqualitäsbeeinträhtigung bei Patienten mit chronischer Urtikaria und Angioödemen. Allergologie, 2016, 39, 6-15.	0.1	6
602	Prevalence and risk factors of chronic urticaria in China: A nationwide crossâ€sectional study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2233-2236.	5.7	6
603	Chronic spontaneous urticaria activity, impact and control as well as their changes are strongly linked, and these links are not affected by angioedema or comorbid inducible urticaria – Results from the validation of the Polish Urticaria Control Test. World Allergy Organization Journal, 2022, 15, 100635.	3.5	6
604	Successful treatment of hereditary angioedema with bradykinin B2â€receptor antagonist icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.	0.8	5
605	The Scope of Pharmacological and Clinical Effects of Modern Antihistamines, With a Special Focus on Rupatadine. World Allergy Organization Journal, 2010, 3, S1-S16.	3.5	5
606	Anti-pruritic Effect of Sertaconazole 2% Cream in Atopic Dermatitis Subjects: A Prospective, Randomized, Double-blind, Vehicle-controlled, Multi-centre Clinical Trial of Efficacy, Safety and Local Tolerability. Acta Dermato-Venereologica, 2014, 96, 792-6.	1.3	5
607	What is urticaria? Expert opinion from the 1st Global Urticaria Forum. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1-2.	2.4	5
608	C1 Inhibitor for Routine Prophylaxis in Patients with Hereditary Angioedema: Interim Results from a European Registry Study. Journal of Allergy and Clinical Immunology, 2016, 137, AB251.	2.9	5
609	Food-dependent cold urticaria: A new variant of physical urticaria. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1400-1402.	3.8	5
610	Validity and responsiveness of the Urticaria Activity and Impact Measure. Annals of Allergy, Asthma and Immunology, 2018, 120, 641-647.	1.0	5
611	Very rarely chronic urticaria can be caused by cancer and if so, resolves with its cure. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1925-1926.	5.7	5
612	H1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2043-2044.	3.8	5

#	Article	IF	CITATIONS
613	Characterization of cowhageâ€induced pruritus in inflamed and nonâ€inflamed skin. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 202-206.	2.4	5
614	Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing. Allergy, Asthma and Immunology Research, 2020, 12, 238.	2.9	5
615	Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series. Allergy, Asthma and Clinical Immunology, 2022, 18, 4.	2.0	5
616	Adaptation and Validation of the Israeli Version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). Israel Medical Association Journal, 2016, 18, 461-465.	0.1	5
617	Development of the Cold Urticaria Activity Score. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2509-2519.	5.7	5
618	The dermatology view of hereditary angioâ€oedema: practical diagnostic and management considerations. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 133-141.	2.4	4
619	Coexistence of Angioedema Alone with Impaired Glucose Tolerance. International Archives of Allergy and Immunology, 2014, 165, 265-269.	2.1	4
620	O10 ―Rupatadine is effective and safe in the treatment of Chronic Spontaneous Urticaria (CSU) in pediatric patients (2â€11 years old). Clinical and Translational Allergy, 2014, 4, O10.	3.2	4
621	Impaired Tâ€cellâ€dependent protection against <i><scp>L</scp>eishmania major</i> infection in <scp>HIV</scp> â€positive patients is associated with worsened disease outcome. Experimental Dermatology, 2015, 24, 302-304.	2.9	4
622	SUBCUTANEOUS SELF-ADMINISTRATION OF LANADELUMAB FOR PROPHYLACTIC TREATMENT IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE). Annals of Allergy, Asthma and Immunology, 2018, 121, S57.	1.0	4
623	Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial. Journal of Allergy and Clinical Immunology, 2019, 143, AB36.	2.9	4
624	Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey findings. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1078-1080.	3.8	4
625	Novel aspects of mast cell and basophil function: Highlights from the 9th meeting of the European Mast Cell and Basophil Research Network (EMBRN)—A Marcus Wallenberg Symposium. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 707-708.	5.7	4
626	The Arabic Urticaria Activity Score and Chronic Urticaria Quality of Life Questionnaire: validation and correlations. International Journal of Dermatology, 2020, 59, 893-901.	1.0	4
627	Validity, reliability, and interpretability of the Brazilian urticaria control test. Allergy and Asthma Proceedings, 2020, 41, e61-e66.	2.2	4
628	Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria. European Annals of Allergy and Clinical Immunology, 2021, 53, 91.	1.0	4
629	HAE patient self-sampling for biomarker establishment. Orphanet Journal of Rare Diseases, 2021, 16, 399.	2.7	4
630	The COVID-19 Pandemic Affects Male Patients With Chronic Spontaneous Urticaria More Than Female Patients. Frontiers in Immunology, 2021, 12, 722406.	4.8	4

#	Article	IF	CITATIONS
631	Adrenaline autoinjector is underprescribed in typical cold urticaria patients. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2224-2229.	5.7	4
632	Therapeutic monoclonal antibodies with a focus on hereditary angioedema. Allergology International, 2023, 72, 54-62.	3.3	4
633	Prevalence and relevance of skin autoreactivity in chronic urticaria. Expert Review of Dermatology, 2009, 4, 655-663.	0.3	3
634	The Scope of Pharmacological and Clinical Effects of Modern Antihistamines, With a Special Focus on Rupatadine: Proceedings from a Satellite Symposium held at the 21st World Allergy Congress, Buenos Aires, December 8, 2009. World Allergy Organization Journal, 2010, 3, S1-S16.	3.5	3
635	Antihistamines in the Treatment of Urticaria. Advances in Experimental Medicine and Biology, 2010, 709, 67-72.	1.6	3
636	Urticaria and angioedema without wheals. , 2012, , 247-261.		3
637	Atopic dermatitis and allergic rhinitis – do coâ€effects in therapy exist?. JDDG - Journal of the German Society of Dermatology, 2012, 10, 221-239.	0.8	3
638	Antihistamine updosing in chronic urticaria - is there enough evidence?. British Journal of Dermatology, 2016, 175, 1134-1135.	1.5	3
639	Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study. Clinical and Translational Allergy, 2018, 8, 11.	3.2	3
640	P154 SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY. Annals of Allergy, Asthma and Immunology, 2019, 123, S28-S29.	1.0	3
641	Flare Size but Not Intensity Reflects Histamine-Induced Itch. Skin Pharmacology and Physiology, 2020, 33, 244-252.	2.5	3
642	Treatment of severe heat urticaria with omalizumab – report of a case and review of the literature. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e489-e491.	2.4	3
643	"Chronic urticaria and obstructive sleep apnea: Is there a significant association?― World Allergy Organization Journal, 2021, 14, 100577.	3.5	3
644	Food-dependent and food-exacerbated symptomatic dermographism: New variants of symptomatic dermographism. Journal of Allergy and Clinical Immunology, 2022, 149, 788-790.	2.9	3
645	Variability of disease activity in patients with hereditary angioedema type 1/2: longitudinal data from the Icatibant Outcome Survey. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2421-2430.	2.4	3
646	Addition of omalizumab to antihistamine treatment in chronic urticaria. Annals of Allergy, Asthma and Immunology, 2020, 125, 217-219.	1.0	3
647	Reply to "Is anti-TPO IgG and total IgE clinically useful for the detection of autoimmune chronic spontaneous urticaria�. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1393-1394.	3.8	3
648	A Novel Method for Total IgE Purification from Human Serum. Journal of Immunology, 2022, 208, 2436-2442.	0.8	3

#	Article	IF	CITATIONS
649	Differential effects of skin nerves on allergic skin inflammation. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 496-497.	5.7	2
650	Effects of a Novel GA2LEN Training Program on Urticaria on the Knowledge of General Practitioners in Saudi-Arabia. World Allergy Organization Journal, 2011, 4, 45-46.	3.5	2
651	Response to: â€~Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal'. British Journal of Dermatology, 2014, 171, 15-16.	1.5	2
652	Chronische spontane Urtikaria – Ein Behandlungspfad für die Diagnosestellung und Therapie in der Praxis. JDDG - Journal of the German Society of Dermatology, 2015, 13, 419-429.	0.8	2
653	Effects of levocetirizine and diphenhydramine on regional glucose metabolic changes and hemodynamic responses in the human prefrontal cortex during cognitive tasks. Human Psychopharmacology, 2018, 33, e2655.	1.5	2
654	Red and itchy bilateral supraorbital swellings. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1503-1506.	0.8	2
655	Angioedema and prescribing of omalizumab for chronic urticaria in countries with limited financial resources. World Allergy Organization Journal, 2019, 12, 100079.	3.5	2
656	P156 LONG-TERM LANADELUMAB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE: HELP OPEN-LABEL EXTENSION STUDY INTERIM FINDINGS. Annals of Allergy, Asthma and Immunology, 2019, 123, S29.	1.0	2
657	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczÄce definicji, klasyfikacji, diagnostyki i leczenia pokrzywki. Alergologia Polska - Polish Journal of Allergology, 2020, 7, 1-28.	0.0	2
658	Adaptación transcultural del cuestionario Mastocytosis Quality of Life questionnaire (MC-QoL) del alemán al castellano. Actas Dermo-sifiliográficas, 2020, 111, 243-248.	0.4	2
659	Travelâ€essociated infectious skin diseases. JDDG - Journal of the German Society of Dermatology, 2020, 18, 730-733.	0.8	2
660	Exaggerated neurophysiological responses to stressor in patients with chronic spontaneous urticaria. Clinical and Experimental Allergy, 2021, 51, 936-938.	2.9	2
661	Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study. Clinical and Experimental Allergy, 2021, 51, 1391-1395.	2.9	2
662	Acetylcholine-induced whealing in cholinergic urticaria – What does it tell us?. Journal of Dermatological Science, 2021, 103, 10-15.	1.9	2
663	Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy. Blood, 2019, 134, 2950-2950.	1.4	2
664	A case of dengue fever presenting with acute urticaria. Asian Pacific Journal of Allergy and Immunology, 2022, , .	0.4	2
665	Allergen-Immuntherapie in der aktuellen COVID-19-Pandemie – ein Positionspapier von ARIA, EAACI, AeDA und DGAKI. Allergologie, 2020, 43, 165-175.	0.1	2

#	Article	IF	CITATIONS
667	IL-9 Production by Regulatory T Cells Recruits Mast Cells That Are Essential for Regulatory T Cell-Induced Immune-Suppression. Blood, 2010, 116, 2782-2782.	1.4	2
668	S3-Leitlinie Urtikaria. Teil 1: Klassifikation und Diagnostik der Urtikaria – deutschsprachige Version der internationalen S3-Leitlinie. Allergologie, 2011, 34, 569-580.	0.1	2
669	A Systematic Review of Aquagenic Urticaria - Subgroups and Treatment Options. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	3.8	2
670	STAT3 gain-of-function is not responsible for low total IgE levels in patients with autoimmune chronic spontaneous urticaria. Frontiers in Immunology, 0, 13, .	4.8	2
671	Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience. World Allergy Organization Journal, 2022, 15, 100664.	3.5	2
672	Searching for Genetic Biomarkers for Hereditary Angioedema Due to C1-Inhibitor Deficiency (C1-INH-HAE). Frontiers in Allergy, 0, 3, .	2.8	2
673	Up-dosing of Desloratadine Reduces Cold Provocation Test Responses in Patients with Cold Urticaria. Journal of Allergy and Clinical Immunology, 2008, 121, 794.	2.9	1
674	Preface. European Journal of Pharmacology, 2016, 778, 1.	3.5	1
675	Identification of Biological and Pharmaceutical Mast Cell―and Basophilâ€Related Targets. Scandinavian Journal of Immunology, 2016, 83, 465-472.	2.7	1
676	Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria. Annals of Allergy, Asthma and Immunology, 2017, 118, 524.	1.0	1
677	Nutzen von Mepolizumab bei einer Patientin mit chronischer spontaner Urtikaria. JDDG - Journal of the German Society of Dermatology, 2018, 16, 476-477.	0.8	1
678	RELATIONSHIP OF TARGET CONCENTRATIONS WITH EFFICACY: RESULTS FROM THE APEX-1 STUDY OF BCX7353. Annals of Allergy, Asthma and Immunology, 2018, 121, S33.	1.0	1
679	LANADELUMAB 300MG EVERY 2 WEEKS EFFECTIVELY PREVENTED HEREDITARY ANGIOEDEMA ATTACKS IN THE HELP STUDY. Annals of Allergy, Asthma and Immunology, 2018, 121, S5.	1.0	1
680	Reply to Ensina et al. Pediatric Allergy and Immunology, 2018, 29, 670-671.	2.6	1
681	P150 ORAL PROPHYLAXIS WITH BCX7353 REDUCES HAE ATTACK RATES AND IS WELL-TOLERATED: APEX-2 STUDY RESULTS. Annals of Allergy, Asthma and Immunology, 2019, 123, S27.	1.0	1
682	Icatibant Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema: Findings from the Icatibant Outcome Survey. Journal of Allergy and Clinical Immunology, 2019, 143, AB43.	2.9	1
683	Articular angioedema in patients with chronic spontaneous urticaria is frequently misdiagnosed as arthritis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3232-3233.e1.	3.8	1
684	Worsening of chronic spontaneous urticaria after intake of hot pepper. Asian Pacific Journal of Allergy and Immunology, 2021, 39, 25-30.	0.4	1

#	Article	IF	CITATIONS
685	Omalizumab Treatment and Outcomes in Chinese Patients with Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, or Both. Journal of Allergy and Clinical Immunology, 2021, 147, AB25.	2.9	1
686	Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE). Journal of Allergy and Clinical Immunology, 2021, 147, AB24.	2.9	1
687	Omalizumab in Chronic Inducible Urticaria: a Real-Life Study of Efficacy, Safety, Predictors of Treatment Outcome, Time to Response and Relapse. Journal of Allergy and Clinical Immunology, 2021, 147, AB26.	2.9	1
688	Pathomechanismus von Angioödemen. Allergologie, 2013, 36, 85-91.	0.1	1
689	Chronic Spontaneous Urticaria and Comorbidities. , 2021, , 77-107.		1
690	WÄĦler unter Medieneinfluss. Berichterstattung, Meinungswandel und Medienwirkungen auf unterschiedlich involvierte WÄĦlergruppen. , 2013, , 291-314.		1
691	Heredit̾s Angio̦dem durch C1- Inhibitor-Mangel. Allergologie, 2019, 42, 170-189.	0.1	1
692	Cold-induced urticaria associated with type I cryoglobulinemia, successfully treated with rituximab. JAAD Case Reports, 2022, 19, 18-20.	0.8	1
693	Disease Impact, Diagnostic Delay, and Unmet Medical Needs of Patients With Cholinergic Urticaria in German-Speaking Countries. Frontiers in Allergy, 2022, 3, .	2.8	1
694	Chronic Urticaria: The Need for Improved Definition. Frontiers in Allergy, 0, 3, .	2.8	1
695	Commentary 8. Experimental Dermatology, 2005, 14, 239-240.	2.9	0
696	Viewpoint 5. Experimental Dermatology, 2006, 15, 924-925.	2.9	0
697	Comment on "Mast Cell-Mediated Remodeling and Fibrinolytic Activity Protect against Fatal Glomerulonephritis― Journal of Immunology, 2006, 177, 1377.1-1377.	0.8	0
698	Interleukin-2 immediate type hypersensitivity?. JDDG - Journal of the German Society of Dermatology, 2008, 6, 080521053342474-???.	0.8	0
699	Atopische Dermatitis und allergische Rhinitis - gibt es Co-Effekte in der Therapie?. JDDG - Journal of the German Society of Dermatology, 2012, 10, 221-236.	0.8	0
700	FRT – FONDATION RENE TOURAINE. Experimental Dermatology, 2015, 24, 803-820.	2.9	0
701	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczÄce definicji, klasyfikacji, rozpoznawania i leczenia pokrzywki: weryfikacja z 2013 roku z poprawkami. Alergologia Polska - Polish Journal of Allergology, 2015, 2, T1-T23.	0.0	0
702	What is new and upcoming in the world of chronic urticaria?. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 5-6.	2.4	0

#	Article	IF	CITATIONS
703	Reply to the letter to the editor on: "In psoriasis, levels of hope and quality of life are linked― Archives of Dermatological Research, 2016, 308, 457-458.	1.9	0
704	Asymmetry of the Receding Hairline in Men With Early Androgenetic Alopecia. Journal of Cutaneous Medicine and Surgery, 2016, 20, 546-549.	1.2	0
705	Early Versus Late Administration of Icatibant in Patients With Hereditary Angioedema. Journal of Allergy and Clinical Immunology, 2017, 139, AB233.	2.9	Ο
706	How does experience affect Management of Chronic Spontaneous Urticaria? A cross sectional study in Latin America. Journal of Allergy and Clinical Immunology, 2017, 139, AB248.	2.9	0
707	041 Prevalence, characteristics and burden of pruritus in chronic dermatoses. Journal of Investigative Dermatology, 2017, 137, S199.	0.7	Ο
708	057 The role of substance P and its receptor NK1R in chronic prurigo: Results from a randomized, controlled trial with topical aprepitant. Journal of Investigative Dermatology, 2017, 137, S202.	0.7	0
709	501 Mechanisms of mast cell and T cell interactions during skin infections. Journal of Investigative Dermatology, 2017, 137, S277.	0.7	0
710	Development of tripe palms and soles in a patient with long preâ€existing systemic mastocytosis and newly developed nonâ€small cell lung cancer. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e151-e153.	2.4	0
711	Sustained Improvement in Work Productivity and Activity Impairment in Chronic Spontaneous Urticaria (CSU) Patients with Omalizumab: Results from Xtend-CIU. Value in Health, 2018, 21, S243.	0.3	0
712	Characterization Of Hereditary Angioedema Attacks Requiring Reinjection Of Icatibant: Findings From The Icatibant Outcome Survey. Journal of Allergy and Clinical Immunology, 2018, 141, AB53.	2.9	0
713	LB1587 Cryptochromes and opsins in human mast cells: putative regulators of their functionality. Journal of Investigative Dermatology, 2018, 138, B20.	0.7	0
714	Reply to Wood etÂal Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 418-419.	5.7	0
715	Translation and Cultural Adaptation of the German Mastocytosis Quality of Life Questionnaire (MC-QoL) Into Spanish. Actas Dermo-sifiliogrÃ _i ficas, 2020, 111, 243-248.	0.4	Ο
716	Ligelizumab for Chronic Spontaneous Urticaria. New England Journal of Medicine, 2020, 382, 579-580.	27.0	0
717	The Pharmacology of Antihistamines. , 2021, , .		0
718	Ligelizumab is more effective in patients with chronic spontaneous urticaria previously treated with omalizumab. Journal of Allergy and Clinical Immunology, 2021, 147, AB158.	2.9	0
719	Einsatz von Biologika bei chronischer spontaner Urtikaria – auch jenseits einer Omalizumab-Therapie?. Allergologie, 2021, 44, 210-217.	0.1	0
720	Analysis of genetic impact on smell impairment in patients with hereditary angioedema typeÂ1 and 2. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1060-1062.	0.8	0

#	Article	IF	CITATIONS
721	Reply to "Proposal for a new classification of vibratory urticaria/angioedema― Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2543-2544.	3.8	0
722	Assessment of urticaria using a selfâ€reported diagnosis tool (SRUD): a multicentre validation study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e652-e654.	2.4	0
723	The Road to Better Urticaria and Angioedema Management. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2243-2244.	3.8	0
724	Evaluation of the Reliability and Validity of the Persian Version of Urticaria Control Test (UCT). Iranian Journal of Allergy, Asthma and Immunology, 0, , .	0.4	0
725	Omalizumab in the Treatment of Urticaria. , 2021, , 167-176.		0
726	Chronic Spontaneous Urticaria. , 2021, , 65-76.		0
727	Other Interventions for Chronic Urticaria. , 2021, , 177-206.		0
728	Praktische Tipps für die Betreuung von Patienten mit Urtikaria. Allergologie, 2007, 30, 211-215.	0.1	0
729	Aktuelle wissenschaftliche Erkenntnisse zur Mastzelle: Bedeutung für die Praxis. Allergologie, 2007, 30, 206-210.	0.1	0
730	Mastocytoses. , 2009, , 1511-1517.		0
731	Mastozytose. , 2012, , 1805-1811.		0
732	Das Paradox der Medienwirkungsforschung. , 2013, , 93-112.		0
733	Neue Therapeutika beim Hereditäen Angioödem – unbeantwortete Fragen beim Hereditäen Angioödem. Allergologie, 2013, 36, 120-127.	0.1	0
734	Hereditäes Angioödem durch C1-Inhibitor-Mangel. Allergologie, 2013, 36, 140-152.	0.1	0
735	Heredit̾s Angio̦dem durch C1-Inhibitor-Mangel 1 1Bei diesem Beitrag handelt es sich um einen genehmigten Nachdruck des Springer Verlags. Ver̦ffentlicht unter: Bork K et al. Heredit̾s Angioödem durch C1-Inhibitor-Mangel. Allergo J, 2012; 21 (2): 109–118 , 2015, , G3.1-G3.14.		0
736	Mastzellen und Basophile. , 2016, , 69-75.		0
737	Mastozytose. , 2016, , 1-7.		0
738	Mastozytose. , 2018, , 1979-1985.		0

#	Article	IF	CITATIONS
739	Rote und juckende bilaterale supraorbitale Schwellungen. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1503-1506.	0.8	0
740	Neue Leitlinien für Urtikaria und hereditäe Angioödeme – was ädert sich? was bleibt gleich?. Allergologie, 2019, 42, 10-17.	0.1	0
741	Wiederkehrende Angioödeme – wie messe und kontrolliere ich das Ansprechen auf Therapie?. Allergologie, 2019, 42, 46-52.	0.1	0
742	Urtikaria: Was gibt's Neues? Biologika und mehr…. Allergologie, 2019, 42, 157-158.	0.1	0
743	Mastocytoses. , 2020, , 1-8.		0
744	Chronic Urticaria. , 2021, , .		0
745	Evaluation of the Reliability and Validity of the Persian Version of Urticaria Control Test (UCT). Iranian Journal of Allergy, Asthma and Immunology, 2021, 20, 423-431.	0.4	0
746	Adrenaline autoinjector is under-prescribed in typical cold urticaria patients living in tropical climate countries. Qatar Medical Journal, 2022, 2022, .	0.5	0
747	Mastocytoses. , 2022, , 1965-1972.		0
748	Use of Patient Reported Outcomes Measures in Asthma Among Pulmonologists: A Pilot Study. , 2022, , .		0